Pancreatitis in patients treated with brentuximab vedotin: A previously unrecognized serious adverse event

Blood

Volumn 123, Issue 18, 2014, Pages 2895-2897

  Gandhi, Mitul D ^a   Evens, Andrew M ^b   Fenske, Timothy S ^c   Hamlin, Paul ^d   Coiffier, Bertrand ^e   Engert, Andreas ^f   Moskowitz, Alison J ^d   Ghosh, Nilanjan ^g   Petrich, Adam M ^a   Lomasney, Jon ^a   Chadburn, Amy ^a   Wood, Gary S ^h   Salva, Katrin ^h   Nardone, Beatrice ^a   Trifilio, Steven M ^a   Raisch, Dennis W ⁱ   West, Dennis P ^a   Gordon, Leo I ^a   Winter, Jane N ^a  

^a NORTHWESTERN UNIVERSITY   (United States)

^b TUFTS MEDICAL CENTER   (United States)

^c MEDICAL COLLEGE OF WISCONSIN   (United States)

^d MEMORIAL SLOAN KETTERING CANCER CENTER   (United States)

^e CENTRE HOSPITALIER LYON SUD   (France)

^f UNIVERSITY HOSPITAL OF COLOGNE   (Germany)

^g LEVINE CANCER INSTITUTE   (United States)

^h UNIVERSITY OF WISCONSIN SCHOOL OF MEDICINE AND PUBLIC HEALTH   (United States)

ⁱ UNIVERSITY OF NEW MEXICO   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

BRENTUXIMAB VEDOTIN; CD30 ANTIGEN; TRIACYLGLYCEROL LIPASE;

ABDOMINAL PAIN; ANTIGEN EXPRESSION; AUTOPSY; CLINICAL FEATURE; DEMOGRAPHY; FATALITY; HUMAN; IMMUNOHISTOCHEMISTRY; LETTER; LYMPHOMA; NAUSEA; PANCREATITIS; PRIORITY JOURNAL; TRIACYLGLYCEROL LIPASE BLOOD LEVEL;

ADULT; AGED; ANTINEOPLASTIC AGENTS; AUTOPSY; FATAL OUTCOME; FEMALE; HODGKIN DISEASE; HUMANS; IMMUNOCONJUGATES; LYMPHOMA, LARGE-CELL, ANAPLASTIC; MALE; MIDDLE AGED; PANCREATITIS; TREATMENT OUTCOME; YOUNG ADULT;

EID: 84903139938     PISSN: 00064971     EISSN: 15280020     Source Type: Journal    
DOI: 10.1182/blood-2014-03-561878     Document Type: Letter

References (7)

1. de Claro RA, McGinn K, Kwitkowski V, et al. U.S. Food and Drug Administration approval summary: brentuximab vedotin for the treatment of relapsed Hodgkin lymphoma or relapsed systemic anaplastic large-cell lymphoma. Clin Cancer Res. 2012;18(21):5845-5849.
2. Younes A, Gopal AK, Smith SE, et al. Results of a pivotal phase II study of brentuximab vedotin for patients with relapsed or refractory Hodgkin's lymphoma. J Clin Oncol. 2012;30(18):2183-2189.
3. Pro B, Advani R, Brice P, et al. Brentuximab vedotin (SGN-35) in patients with relapsed or refractory systemic anaplastic large-cell lymphoma: results of a phase II study. J Clin Oncol. 2012;30(18):2190-2196.
4. Younes A, Bartlett NL, Leonard JP, et al. Brentuximab vedotin (SGN-35) for relapsed CD30-positive lymphomas. N Engl J Med. 2010;363(19): 1812-1821.
5. Urru SA, Mariotti E, Carta P, et al. Acute pancreatitis following brentuximab vedotin therapy for refractory Hodgkin lymphoma: a case report [published online ahead of print February 4, 2014]. Drugs R D.
6. Taylor CR, Levenson RM. Quantification of immunohistochemistry - issues concerning methods, utility and semiquantitative assessment II. Histopathology. 2006;49(4):411-424. (Pubitemid 44401549)
7. Whitcomb DC. Genetic risk factors for pancreatic disorders. Gastroenterology. 2013;144(6):1292-1302.